CAR-T Therapy Versus Bispecific Antibodies

Written by The Life Science Feed Editorial Team · Published 1 June 2026 · Edited by Sarah Mitchell

KEY TAKEAWAYS

- Allogeneic off-the-shelf CAR-T eliminates manufacturing delays and enables redosing - shorter persistence remains the key challenge vs autologous
- In vivo CAR-T (gene delivery directly to T cells via nanoparticles) is in early clinical development - potentially transformative for access within 5 years
- Bispecific antibodies (teclistamab, glofitamab, mosunetuzumab): off-the-shelf, impressive ORR/CR in relapsed disease, lower barrier to access - likely complementary to CAR-T, not competitive
- CAR-NK cells: early data shows activity without GVHD, CRS, or ICANS - next frontier for off-the-shelf immune cell therapy

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. Mailankody S et al. ALLO-501. J Clin Oncol. 2023
2. 2. Moreau P et al. MajesTEC-1. N Engl J Med. 2022;387:495-505
3. 3. Linton K et al. CELESTIMO. Lancet Oncol. 2023
4. 4. Liu E et al. CAR-NK. N Engl J Med. 2020;382:545-553

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com